An FDA-approved Phase 1/2a clinical trial is underway to evaluate the safety an therapeutic potential of SB623. This clinical trial will enroll a total of 18 patients that had an ischemic stroke within the past 3 years.

All transportation and study-related costs will be covered.

For more information, or to see if you or a loved one qualifies, please contact SanBio at 1+650-625-8965.

Additional information about our FDA-approved clinical trial may be found at the US National Institutes of Health Clinical Trials website.